These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12365009)

  • 1. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
    Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM
    Cancer; 2002 Oct; 95(8):1629-36. PubMed ID: 12365009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
    Rini BI; Vogelzang NJ; Dumas MC; Wade JL; Taber DA; Stadler WM
    J Clin Oncol; 2000 Jun; 18(12):2419-26. PubMed ID: 10856102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
    George CM; Vogelzang NJ; Rini BI; Geoffroy FJ; Kollipara P; Stadler WM
    Ann Oncol; 2002 Jan; 13(1):116-20. PubMed ID: 11863091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
    Ryan CW; Vogelzang NJ; Stadler WM
    Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
    Amato RJ; Khan M
    Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
    Shan YS; Lin PW
    Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
    Rini BI; Weinberg V; Small EJ
    Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
    Kraemer A; Hauser S; Kim Y; Gorschlüter M; Müller SC; Brossart P; Schmidt-Wolf IG
    Ger Med Sci; 2009 Jun; 7():Doc04. PubMed ID: 19675744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
    Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
    J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
    Awada A; Biganzoli L; Cufer T; Beex L; Lohrisch C; Batter V; Hamilton A; Nooij M; Piccart M
    Eur J Cancer; 2002 Apr; 38(6):773-8. PubMed ID: 11937310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
    Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
    Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ; Morgan M; Rawat A
    Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
    Amato RJ; Rawat A
    Invest New Drugs; 2006 May; 24(3):171-5. PubMed ID: 16086096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
    Van Veldhuizen PJ; Hussey M; Lara PN; Mack PC; Gandour-Edwards R; Clark JI; Lange MK; Crawford DE
    Am J Clin Oncol; 2009 Oct; 32(5):453-9. PubMed ID: 19487915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
    Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
    Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
    Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
    Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
    El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
    J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.